Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identifying the Therapeutic Potential and Molecular Mechanism of lnc-Hoxb3os in ADPKD

Award Number: R01DK143971
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Identifying the Therapeutic Potential and Molecular Mechanism of lnc-Hoxb3os in ADPKD - PROJECT SUMMARY Polycystic kidney disease (PKD) is characterized by the formation of cysts, which originate from the epithelial tubules of the nephron. The most common form of PKD, autosomal dominant polycystic kidney disease (ADPKD), is primarily caused by mutations in two genes, PKD1 and PKD2. More than 600,000 people in the United States are affected by this disease. About half of those diagnosed with ADPKD will progress to end-stage renal failure, necessitating dialysis or kidney transplantation. The pathophysiology of ADPKD is incompletely understood, and only one FDA-approved treatment (tolvaptan) exists. Accordingly, there is an urgent need to elucidate the molecular mechanisms of disease onset and progression toward the goal of identifying new drug targets and developing the next generation of effective therapeutics. Long noncoding RNAs (lncRNAs) – defined by a length >200 nucleotides and absence of a long open reading frame-are a class of non-protein-coding RNAs implicated in a range of diseases. The nature and extent of involvement of lncRNAs in ADPKD are not well known. Our long-term goal is to identify therapeutically targetable lncRNAs that prevent or mitigate cyst formation and/or progression in ADPKD. We recently identified Hoxb3os as the first lncRNA that is directly involved in mouse PKD. Hoxb3os was reduced in cystic kidneys from multiple mouse models of PKD, its ablation exacerbated cystogenesis in rapid- and slow-progressing PKD mouse models. The human ortholog, HOXB-AS1, is similarly decreased in human ADPKD kidneys and in cystic kidney organoids. At the molecular level, we discovered that Hoxb3os RNA associates with 16 proteins in kidney cells, including PKM2 and ATP synthase (ATP5F1A/B), two nodes central to ADPKD metabolism. Hoxb3os-mutant cells displayed increased glycolysis and enhanced mitochondrial superoxide production. Our central hypothesis is that Hoxb3os/HOXB-AS1 suppresses cystogenesis by inhibiting glycolysis and reducing mitochondrial superoxide through direct interactions with PKM2 and ATP5F1A/B, respectively. To test this hypothesis, we will 1) determine whether re- expressing Hoxb3os in mouse PKD and HOXB-AS1 in human ADPKD models reduces cyst burden and improves functional readouts, and 2) identify the mechanisms by which Hoxb3os/HOXB-AS1 regulates glycolysis and mitochondrial superoxide. Because glycolytic reprogramming and mitochondrial ROS are key drivers of ADPKD, these studies will define a lncRNA-guided metabolic control axis and lay the groundwork for RNA-based therapeutics and companion diagnostics for cystic kidney disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $785,689 )
2026	2026	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	W5510 FRANKS MELVILLE MEMORIAL LIBRARY	STONY BROOK	NY	11794	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/28/2026	NEW	$785,689
														Subtotal = $785,689

Grand Total All Awards = $785,689

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identifying the Therapeutic Potential and Molecular Mechanism of lnc-Hoxb3os in ADPKD

Award Number: R01DK143971

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer